A Systematic Review of Long-Acting <i>β</i>2-Agonists Versus Higher Doses of Inhaled Corticosteroids in Asthma

Castro-Rodriguez, José A.; Rodrigo, Gustavo J.

doi:10.1542/peds.2012-0162

Cited by 21 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, reduced height‐SDS was previously reported in several studies on individuals with asthma alone and in patients on inhaled steroids: a dose‐dependent decreased height was reported in pediatric and adolescent individuals with asthma with inhaled glucocorticoid treatment and has recently been confirmed by a Cochrane review …”

Section: Discussionmentioning

confidence: 59%

Asthma in children and adolescents with type 1 diabetes in Germany and Austria: Frequency and metabolic control

Hörtenhuber

Kieß²,

Fröhlich‐Reiterer

et al. 2017

Pediatr Diabetes

View full text Add to dashboard Cite

In our DPV-database, frequency of asthma and T1D seems similar to the prevalence of asthma in the healthy German background population. The concomitant diagnosis of asthma and T1D had minor influence on metabolic control and diabetes complication rate, although there was no difference in HbA1c overall. Patients with both diseases seem to be slightly growth restricted and require slightly higher insulin doses.

show abstract

Section: Discussionmentioning

confidence: 59%

Asthma in children and adolescents with type 1 diabetes in Germany and Austria: Frequency and metabolic control

Hörtenhuber

Kieß²,

Fröhlich‐Reiterer

et al. 2017

Pediatr Diabetes

View full text Add to dashboard Cite

show abstract

“…Currently, therapeutics in asthma include beta-agonists, oral and inhaled corticosteroids, anticholinergics, phosphodiesterase inhibitors, molecules that inhibit leukotriene production (zileuton, zafirlukast and montelukast) and anti-IgE monoclonal antibody (omalizumab) 117, 118 . Omalizumab is the first anti-IgE therapy to demonstrate efficacy and to be approved by the FDA for asthma 67 .…”

Section: Basophils and Allergic Inflammation: Pathogenesis And Implicmentioning

confidence: 99%

Basophils and allergic inflammation

Siracusa

Kim

Spergel

et al. 2013

Journal of Allergy and Clinical Immunology

264

209

View full text Add to dashboard Cite

Basophils were discovered by Paul Ehrlich in 1879 and represent the least abundant granulocyte population in mammals. The relative rarity of basophils and their phenotypic similarities with mast cells resulted in this cell lineage being historically overlooked, both clinically and experimentally. However, recent studies in humans and murine systems have shown that basophils perform non-redundant effector functions and significantly contribute to the development and progression of TH2 cytokine-mediated inflammation. Although the potential functions of murine and human basophils have provoked some controversy, recent genetic approaches indicate that basophils can migrate into lymphoid tissues and, in some circumstances, cooperate with other immune cells to promote optimal TH2 cytokine responses in vivo. This article provides a brief historical perspective on basophil-related research and discusses recent studies that have identified previously unappreciated molecules and pathways that regulate basophil development, activation and function in the context of allergic inflammation. Further, we highlight the unique effector functions of basophils and discuss their contributions to the development and pathogenesis of allergic inflammation in human disease. Finally, we discuss the therapeutic potential of targeting basophils in preventing or alleviating the development and progression of allergic inflammation.

show abstract

“…Patients with acute asthma symptoms are, therefore, administered drugs to stimulate expansion of the trachea, and to reduce goblet cell inflammation and mucus secretion. β2-agonists are commonly used to expand the trachea during asthma attacks 8,9. However, recent studies have found that long-term inhalation of β2-agonists leads to the development of drug tolerance, requiring the patient to inhale an increased dose of drug in order to suppress acute asthma symptoms 8.…”

Section: Introductionmentioning

confidence: 99%

“…β2-agonists are commonly used to expand the trachea during asthma attacks 8,9. However, recent studies have found that long-term inhalation of β2-agonists leads to the development of drug tolerance, requiring the patient to inhale an increased dose of drug in order to suppress acute asthma symptoms 8. There is, therefore, a need to identify viable therapeutic alternatives to current asthma medications.…”

Section: Introductionmentioning

confidence: 99%

Oral Lovastatin Attenuates Airway Inflammation and Mucus Secretion in Ovalbumin-Induced Murine Model of Asthma

Liou

Cheng

Huang

et al. 2014

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

PurposeLovastatin is an effective inhibitor of cholesterol synthesis. A previous study demonstrated that lovastatin can also suppress airway hyperresponsiveness (AHR) in murine model of asthma. We aimed to investigate the effect of lovastatin on mucus secretion and inflammation-associated gene expression in the lungs of murine model of asthma.MethodsFemale BALB/c mice were sensitized and challenged with ovalbumin (OVA) by intraperitoneal injection, and orally administered lovastatin from days 14 to 27 post-injection. Gene expression in lung tissues was analyzed using real-time polymerase chain reaction. AHR and goblet cell hyperplasia were also examined. BEAS-2B human bronchial epithelial cells were used to evaluate the effect of lovastatin on the expression of cell adhesion molecules, chemokines, and proinflammatory cytokines in vitro.ResultsWe showed that lovastatin inhibits the expression of Th2-associated genes, including eotaxins and adhesion molecules, in the lungs of murine model of asthma. Mucin 5AC expression, eosinophil infiltration and goblet cell hyperplasia were significantly decreased in the lung tissue of murine model of asthma treated with lovastatin. Furthermore, lovastatin inhibited AHR and expression of Th2-associated cytokines in bronchoalveolar lavage fluid. However, a high dose (40 mg/kg) of lovastatin was required to decrease specific IgE to OVA levels in serum, and suppress the expression of Th2-associated cytokines in splenocytes. Activated BEAS-2B cells treated with lovastatin exhibited reduced IL-6, eotaxins (CCL11 and CCL24), and intercellular adhesion molecule-1 protein expression. Consistent with this, lovastatin also suppressed the ability of HL-60 cells to adhere to inflammatory BEAS-2B cells.ConclusionsThese data suggest that lovastatin suppresses mucus secretion and airway inflammation by inhibiting the production of eotaxins and Th2 cytokines in murine model of asthma.

show abstract

A Systematic Review of Long-Acting β2-Agonists Versus Higher Doses of Inhaled Corticosteroids in Asthma

Abstract: There were no statistically significant group differences between ICS+LABA and double doses of ICS in reducing the incidence of asthma exacerbations but it did decrease the risk comparing to higher than double doses of ICS.

Cited by 21 publications

References 33 publications

Asthma in children and adolescents with type 1 diabetes in Germany and Austria: Frequency and metabolic control

Asthma in children and adolescents with type 1 diabetes in Germany and Austria: Frequency and metabolic control

Basophils and allergic inflammation

Oral Lovastatin Attenuates Airway Inflammation and Mucus Secretion in Ovalbumin-Induced Murine Model of Asthma

Contact Info

Product

Resources

About